Nature Communications (Feb 2021)
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
- Ryan Kolb,
- Umasankar De,
- Sajid Khan,
- Yuewan Luo,
- Myung-Chul Kim,
- Haijun Yu,
- Chaoyan Wu,
- Jiao Mo,
- Xin Zhang,
- Peiyi Zhang,
- Xuan Zhang,
- Nicholas Borcherding,
- Daniel Koppel,
- Yang-Xin Fu,
- Song Guo Zheng,
- Dorina Avram,
- Guangrong Zheng,
- Daohong Zhou,
- Weizhou Zhang
Affiliations
- Ryan Kolb
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Umasankar De
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Sajid Khan
- Department of Pharmacodynamics, College of Pharmacy, University of Florida
- Yuewan Luo
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Myung-Chul Kim
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Haijun Yu
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Chaoyan Wu
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Jiao Mo
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- Xin Zhang
- Department of Pharmacodynamics, College of Pharmacy, University of Florida
- Peiyi Zhang
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida
- Xuan Zhang
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida
- Nicholas Borcherding
- Department of Pathology, University of Iowa
- Daniel Koppel
- University of Florida Health Cancer Center, University of Florida
- Yang-Xin Fu
- Department of Pathology, University of Texas Southwestern Medical Center
- Song Guo Zheng
- Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center
- Dorina Avram
- University of Florida Health Cancer Center, University of Florida
- Guangrong Zheng
- University of Florida Health Cancer Center, University of Florida
- Daohong Zhou
- University of Florida Health Cancer Center, University of Florida
- Weizhou Zhang
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida
- DOI
- https://doi.org/10.1038/s41467-021-21573-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
Targeting regulatory T cells (Treg) represents a therapeutic option to abrogate tumor-associated immune suppression. Here the authors show that pharmacological degradation of BCL-XL preferentially induces apoptosis of tumor-infiltrating Treg, promoting CD8 T cell activation and anti-tumor immune responses in preclinical cancer models.
